December 2020 FDA Recall Ketorolac Tromethamine by Fresenius Kabi Usa, Llc
D-0184-2021 - Presence of Particulate Matter - found in reserve sample vials at the firm.

This Class II drug recall was voluntarily initiated by Fresenius Kabi Usa, Llc on December 17, 2020 for the product Ketorolac Tromethamine. The FDA reported the reason for recall as presence of particulate matter - found in reserve sample vials at the firm.. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0184-2021

Reason for Recall
Presence of Particulate Matter - found in reserve sample vials at the firm.
Initiated
12-17-2020
Reported
01-06-2021
Quantity
490,633 vials

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Fresenius Kabi USA, LLC
USA Nationwide and Puerto Rico
Ketorolac Tromethamine Injection, USP, 60 mg per 2 mL (30 mg per mL), packaged in 2 mL Single Dose Vial, Rx only, Fresenius Kabi, Lake Zurich, IL 60047, NDC 63323-162-02

Batch or Lot Expiration Information

Batch# 6121125, Exp 02/2021